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Background/aim: To investigate the optimal protocol for frozen-thawed embryo transfer (FET) cycles in patients who previously had
a cycle cancellation due to uterine peristalsis (UP).
Materials and methods: Thirty-four patients with previous embryo transfer (ET) cancellation due to UP during artificial cycle
(AC) were included retrospectively. In the proceeding cycle, endometrium was prepared with AC (n: 23) in AC-FET group or with
stimulated cycle that contains letrozole (L) (n: 11) in L-FET group. Intravenous bolus dose of 6.75 mg atosiban (Tractocile; Ferring
Pharmaceuticals, Switzerland) injection was performed to all patients of AC-FET group due to UP ≥ 4/min on the planned ET day of
proceeding cycle. Atosiban was not used in L-FET group. Primary outcome was live birth rate (LBR) per ET. Secondary outcomes were
clinical pregnancy rate (CPR) per ET, implantation rate (IR), cycle cancellation rate.
Results: The baseline characteristics such as age, body mass index, antral follicle count, duration of infertility, and the number of prior
in vitro fertilization attempts of each group were similar. The IR, CPR per ET, LBR per ET, CPR per cycle and LBR per cycle were
significantly higher; cycle cancellation rates were significantly lower in L-FET group as compared to the AC-FET group.
Conclusion: Endometrial preparation with letrozole significantly improves CPR and LBR in FET cycles of patients with previous cycle
cancellations due to UP.
Key words: Uterine peristalsis, frozen-thawed cycle, embryo transfer, letrozole, atosiban

1. Introduction
Frozen-thawed embryo transfer (FET) has gained
importance in assisted reproduction technology (ART)
worldwide with the improvements in the vitrification
techniques and increased pregnancy rates [1]. It
gives the opportunity of storing surplus embryos and
transferring them in more suitable conditions especially
in cases of increased risk of ovarian hyperstimulation
syndrome (OHSS) [2] and in the presence of endometrial
disturbances, with lower cost and simpler than repeated
fresh cycles [3].
Despite the improvements in ART, in vitro
fertilization (IVF) success rate in terms of live birth per
cycle is 26.9% [4]. Two important factors that affect
implantation and consequently IVF outcome are embryo
quality and endometrial receptivity [5–9]. Endometrial
thickness and pattern should be appropriate and blood
flow should be sufficient for a receptive endometrium

[8,10–12]. Endometrial receptivity and implantation
has been impaired in a stimulated cycle as a result of
supraphysiological endocrine milieu [13–15].
Ovarian stimulation cycle differs from a natural cycle
by means of endocrine milieu with low progesterone [16]
and supraphysiological level of estradiol [17]. Elevated
serum estradiol has deleterious effects on endometrium by
changing protein expressions [18]. It also effects directly
embryo and disrupts embryo adhesion [19]. Another
undesirable effect of ovarian stimulation is thought to be
increase in uterine activity due to exaggerated oxytocin
action stimulated by elevated levels of estradiol [20]. It
was shown that expressions of uterine oxytocin mRNA
and uterine oxytocin receptors were ovarian hormonedependent. Oxytocin produced by endometrium is highest
in the midcycle in natural cycles [21,22] to stimulate
myometrial activity of nonpregnant uterus and plays a role
in sperm and egg transport and implantation [23]. It is
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also increased 300-fold during pregnancy as a stimulatory
effect of estrogens [24].
Uterine peristalsis (UP) was detected in 30% of patients
before embryo transfer (ET) [25] and implantation rates
in cases of UP were 3-fold lower compared with silent
uteri [26]. Several medical treatments have been used for
UP treatment [27]. Due to the lack of large sample sized
randomized controlled studies, to date there is not any
confirmed diagnostic tool and therapeutic approach for
UP [8].
As with the treatment of UP, there are also controversies
regarding the best FET protocol [1,28]. The protocols used
for FET are natural cycle, modified natural cycle, artificial
cycle (AC-FET) with or without suppression, mild ovarian
stimulation with gonadotropins and aromatase inhibitors
as letrozole [1]. Letrozole, third generation aromatase
inhibitor, is a short half-life agent for ovulation induction
that leads generally to monofollicular development with
maintenance of normal central feedback and not blocking
the estrogen receptors [29]. It was shown that letrozole
increased endometrial receptivity markers [30]. While
letrozole inhibits the conversion of androgen to estradiol
and causes much lower estradiol levels than the natural
cycle, it does not cause negative effects on endometrial
thickness [6]. Letrozole was indirectly used for endometrial
preparation in FET cycles of patients with polycystic ovary
syndrome (PCOS) [6,29,31].
The aim of the study was to investigate the effects
of letrozole-stimulated endometrial preparation in
the patients with a history of UP and to compare the
pregnancy outcomes of L-FET and AC-FET cycles in
these patients. The hypothesis was that letrozole usage for
endometrial preparation can lead to lower estradiol levels
and decreased production of endometrial oxytocin, which
triggers UP. To the best of our knowledge, this is the first
study that compares AC and letrozole-stimulated cycle in
patients with previous cycle cancellation due to UP.
2. Materials and methods
Patients whose embryo transfers (ET) were cancelled
in previous AC-FET cycle due to uterine contractions
(UC) ≥ 4/min that were realized on routine transvaginal
ultrasonography (TVUSG) controls and persisted on
planned ET day were included in this retrospective pilot
study. All included patients were treated for a FET cycle
from January 2019 to May 2019 in NovaArt IVF Center.
Considering the option of administering atosiban if UP
recurs, AC was restarted in one group; while the other group
was given letrozole for endometrial preparation. Exclusion
criteria were the women aged >42 years, antral follicle
count (AFC) < 5, uterine pathologies as adenomyosis,
uterine anomaly, uterine fibroids, and hydrosalpinges.
Embryo quality was assessed after warming according to

1366

the number and regularity of blastomeres and the degree
of fragmentation. The institutional review board and ethics
committee approved the study.
In L-FET group, endometrium was prepared with
letrozole (Femara; Novartis, Switzerland) 5 mg daily for 5
days beginning on day 3 of menses. When preovulatory
follicle reached 17 mm; serum E2, LH, and progesterone
levels were checked every day. When endometrial thickness
was ≥7 mm and serum E2 level was >150 pg/mL with the
presence of corpus luteum or in the case of corpus luteum
uncertainty in TVUSG if progesterone level above 1.5 ng/
mL was detected after LH peak, vaginal progesterone (400
mg/day; Progestan; Kocak Farma, Turkey) was started.
In AC-FET protocol, endometrium was prepared
with estradiol valerate 2 mg three times daily (Estrofem;
Novo Nordisk, Turkey) beginning on day 3 of menses. If
endometrial thickness was ≥7 mm and serum E2 level ws
>150 pg/mL, vaginal progesterone (400 mg/day; Progestan;
Kocak Farma, Turkey) was started. In both protocol, ET
was scheduled on the 4th day for cleavage embryo or 6th
day for blastocyst. Luteal support was continued until 10
weeks of gestation if pregnancy occurs.
Endometrial thickness and pattern were evaluated with
TVUSG (Aloka SSD-1000, Japan) with a 5 MHz transvaginal
probe during routine examinations. The number of UP per
minute was calculated by directly counting the peristaltic
waveforms seen in the endometrium in the sagittal plane
on transvaginal ultrasound examination for 1 min. All
TVUSG examinations were performed with the same
single sonographer (I.S). The patients that had UC ≥ 4/
min were examined with TVUSG on the planned ET day
again. According to previous data, it was demonstrated
that clinical pregnancy rate (CPR) was 50% lower in
patients that have UC ≥ 4/min on ET day [26,32]. If
uterine peristalsis ≥4/min was detected, i.v bolus dose of
6.75 mg atosiban (Tractocile; Ferring Pharmaceuticals,
Switzerland) injection was performed in the AC-FET
group before thawing. If UP continues 1 h later, the thawing
procedure was not performed and ET was cancelled. ET
was performed 2 h after the thawing procedure if UP did
not continue. The number of transferred embryos was
decided according to Turkish Health Ministry restrictions
as mandatory single ET and conditional two ET rule. None
of the patients were given adjuvant treatments.
Primary outcome was live birth rate (LBR). Secondary
outcomes were CPR, implantation rate (IR), cycle
cancellation rate, and endometrial thickness. Implantation
rate was calculated by dividing the total number of
gestational sacs on ultrasound by the total number of
embryos transferred. Pregnancy test was performed by
measuring serum βhCG level at 12 days after embryo
transfer (ET) and intrauterine pregnancy was confirmed
by using TVUSG 2 weeks after a positive pregnancy test.
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Clinical pregnancy was defined as intrauterine positive
fetal cardiac activity in the ultrasound examination. LBR
was defined as the birth of a fetus older than 32 weeks.
We did not perform a power analysis due to the
retrospective design of our study. In a power analysis we
performed for a future prospective study, the sample size
computed by an online analyzer1 demonstrated that for an
expected difference of incidences between the groups (20%
vs 40%) with 5% level of significance and a power of 80%, a
total of 162 patients (81 patients per group) were required.
All statistical analyses were performed using SPSS v. 21
(IBM SPSS Statistics for Windows, Version 21.0. Armonk,
NY: IBM Corp). Continuous variables with nonnormal
distribution were presented as median (min–max) and
compared with the Mann–Whitney U test. Fisher’s exact
test was used for comparison of categorical variables; the
chi-squared test was used for comparison of implantation
rates. p-values <0.05 were considered to be statistically
significant.
3. Results
Thirty-four patients with previous ET cancellation due
to UP were included for final analysis. Endometrium was
prepared for ET with artificial cycle that contains estradiol
and progesterone supplementation (n: 23) and with
stimulated cycle that contains letrozole (n: 11) (Figure).
The baseline characteristics of each group were presented
in Table 1. The groups were similar with respect to age,
body mass index (BMI), duration of infertility, antral
follicle count, and number of prior in vitro fertilization
attempts.
The cycle characteristics and outcomes are presented
in Table 2. Progesterone level on cycle day 2, endometrial
thickness on ET day, and number of top quality embryos
transferred were similar between two groups. The peak
estradiol level (184 [150–316] vs 250 [150–470], p < 0.05)
was significantly lower in the L-FET group as compared
to the AC-FET group. Atosiban was administered in all
patients of the AC-FET group due to UP that recurred
in proceeding cycle and persisted on planned ET day.
Atosiban administration rate was 100% in the AC-FET
group and 0% in the L-FET group. Four cycles in the ACFET group were cancelled due to UC ≥ 4/min despite
atosiban injection on planned ET day. One cycle that had
UC ≥ 4/min on planned ET day in the L-FET group were
cancelled without atosiban injection. In the remaining
patients, ET procedure was performed. The implantation
rates (55.5% vs 11.7%); CPR per ET (90% vs. 15.8%); LBR
per ET (70% vs. 5.3%) and CPR per cycle (81% vs. 13%);
LBR per cycle (63% vs. 4.3%) were significantly higher in
the L-FET group as compared to the AC-FET group. Cycle
cancellation rates (9% vs 17.4%) were significantly lower
in the L-FET group when compared to the AC-FET group.
1

4. Discussion
Letrozole-stimulated endometrial preparation is an
option for FET cycles especially in patients with ovulatory
dysfunction [6,29,31]. To the best of our knowledge, this is
the first study that investigates the potential advantages of
letrozole in patients with a previous cycle cancellation due
to uterine peristalsis and compares it with artificial cycle
in terms of live birth rate. The present study demonstrated
statistically significantly improved IR, CPR, and LBRs in
L-FET cycles when compared with AC-FET cycles in this
patient group. The difference in the cycle outcomes can
be attributed to the increased endometrial receptivity due
to decreased UP in the L-FET group while the numbers
of top-quality embryos transferred were similar between
groups.
The underlying cause of implantation failures are
impaired endometrial receptivity in two-thirds of cases
and embryo quality in one-third [33]. Implantation is a
crosstalk between endometrium, embryo, and maternal
immune system [34,35]. An appropriate endometrial
thickness and pattern, a sufficient blood flow [8,10–12]
and a silent uterus [13–15,36] are needed for a receptive
endometrium. It was shown that CPR was 50% lower in
patients with UP ≥ 4/min than patients that have UP < 4/
min and success rates of IVF/ET decrease 3-fold in cases
of pronounced uterine contractions [26]. In our study, we
selected a period of 1 min for assessment of UP according
to previous data. This period was sufficient for detecting
profound UP without any patient discomfort. The direction
of UP was not noted as there was not any evidence that has
shown its impact on implantation [26,32].
Uterine contractile activity is essential for reproduction.
UP from fundus to cervix is needed to empty uterine
cavity in early follicular phase. In the late follicular
and periovulatory phases, UP from cervix to fundus
is needed for sperm transport. In luteal phase, uterus
becomes a relatively silent place for embryo implantation
[27,37]. However, in ovarian stimulation cycles, both the
catheterization of uterus during ET [38] and elevated
estradiol levels can trigger excessive uterine contractions
that can expel embryos from the uterus and decrease the
pregnancy rates [15,26,39,40]. In the absence of uterine
mechanical manipulation and uterine disorders like
endometriosis, adenomyosis, leimyoma, and polyp; the
mechanism underlying UP is exaggerated oxytocin action
that is stimulated by elevated levels of estradiol [20,27].
Several medical treatments such as progesterone,
anticholinergic
agents,
prostaglandin
synthetase
inhibitors, beta adrenergic receptor antagonists, and
oxytocin receptor antagonists have been used for UP
treatment [27]. It was demonstrated that progesterone,
anticholinergic agents, and oxytocin receptor antagonists

https://clincalc.com/stats/samplesize.aspx
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Embryo transfer cancellation due
to uterine peristalsis (n:34)

Letrozole-stimulated cycle (n:11)8

Artificial cycle (n:23)

9

Persisted uterine peristalsis on 13
ET day (n: 23)
14

Persisted uterine peristalsis
on ET day
(n: 1)

n

Atosiban administration (n:23)

Atosiban
administration (n: 0)

Thawing cancellation
due to persisted
uterine peristalsis

Embryo transfer cancellation due
19
to uterine peristalsis (n: 1)

ET
performed
cycle (n:19)

ET
performed
cycle (n:10)

20

(n: 4)

Figure. Flow diagram of patients with uterine peristalsis, atosiban
administration, thawing cancellation, and embryo transfer (ET).

reduce UP in observational studies [27]. Atosiban is a
combined oxytocin/vasopressin V1A antagonist that is
used in the management of preterm labor. It is an effective,
well-tolerated [41], and embryo-safe drug [42]. It was first
used in IVF in a patient with recurrent implantation failure
and pregnancy was documented as a case report in 2007
[43] and then the same author demonstrated that atosiban
reduces uterine contractility and intrauterine prostaglandin
F2α production and increases uterine blood supply [20].
Moraloglu et al. reported significant improvement in IR and
CPR in atosiban group [44]. However, in a larger sample
sized randomized double blind placebo controlled study, it
was demonstrated that atosiban given around ET did not
improve LBR in a general IVF population [37]. In both of
these studies uterine contractions were not measured. Lan
et al. showed that atosiban usage improved IR and CPR
in women with recurrent implantation failure undergoing
an AC-FET cycle when compared to previous cycles of
patients [45]. Unlike the previous mentioned studies,
Lan et al. measured uterine contractions and showed
significant decrease of uterine contractions after atosiban
administration [45]. In all of these studies, atosiban was
used 3 h around ET and the last dose was given 2 h after
ET. In our study, we had used one dose of i.v. bolus 6.75 mg
atosiban and ET was performed 2 h after thawing if UP did

1368

not continue. However, IR, CPR, and LBR rates remained
significantly lower when compared to the L-FET group
that does not have UP on ET day. The reason why we did
not find any benefit of atosiban on pregnancy rates in ACFET group may be the lower dose and duration of atosiban
administration. Due to the short half-life of atosiban,
beneficial effects on reduction of contractions may not last
through the implantation period and so may not improve
pregnancy rates. A prolonged atosiban infusion or adding
other drugs as nonsteroidal antiinflammatories can be
an option [37]. However, further randomized trials are
needed for accurate conclusions.
It seems to be more logical to prevent the stimulation
of UP rather than treat it. A prolonged time of atosiban
infusion is not feasible and cost-effective. As it is known,
expressions of uterine oxytocin mRNA and uterine
oxytocin receptors were ovarian hormone-dependent and
increases with stimulatory effects of estrogens [5,21,22,24].
Therefore, it seems that the main goal must be maintaining
lower levels of estradiol in FET cycles of previous UP cases.
In FET cycles, mild ovarian stimulation (OS) with
aromatase inhibitors (AI) as letrozole gains popularity
nowadays. In a recent metaanalysis, it was demonstrated
that OS with gonadotropin or AI had significantly higher
clinical pregnancy and live birth rates when compared
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Table 1. Comparison of patient characteristics between the AC-FET and L-FET groups.
AC-FET group
(n:23)

L-FET group
(n:11)

p-value

Age (years)

29 (20–41)

32 (24–42)

NS

BMI(kg/m )

23.6 (22.3–24.5)

AFC (n)

15 (5–20)

15 (8–16)

NS

Duration of infertility (years)

4 (1–13)

4 (1–20)

NS

Prior IVF attempts (n)

3 (1–7)

2 (1–8)

NS

Etiology of infertility (n,%)
Unexplained infertility
Male infertility
Tubal factor
Mixed

12 (52%)
7 (30%)
2 (8.6%)
2 (8.6%)

6 (54%)
3 (27%)
1 (9%)
1 (9%)

Freezing indications (n,%)
Premature progesterone rise
OHSS
Remaining embryo

7 (30.4%)
5 (21.7%)
11 (47%)

3 (27%)
2 (18%)
6 (54%)

Variables

2

24.2 (22.9–24.4)

NS

Data are presented as median (range) and number (percentages).
AC-FET: artificial cycle-frozen thawed embryo transfer; AFC: antral follicle count;
BMI: body mass index; IVF: in vitro fertilization; L-FET: letrozole-frozen thawed embryo transfer;
OHSS: ovarian hyperstimulation syndrome; NS: not statistically significant.
Table 2. Cycle characteristics and outcomes of each group.
Variables
No. of top-quality embryos transferred (n) a
Endometrial thickness(mm)

a

Progesterone level on the day of cycle day 2 (ng/mL)

AC-FET group

L-FET group

p-value

2 (1–2)

2 (1–2)

NS

10.9 (8–15)

10 (10–14)

NS

0.21 (0.05–0.76)

0.11 (0.05–0.23)

NS

Peak estradiol level (pg/mL)a

250 (150–470)

184 (150–316)

0.014

Cycle cancellation rate

17.4% (4/23)

9% (1/11)

<0.001

11.7% (4/34)

55.5% (10/18)

<0.001

15.8% (3/19)

90% (9/10)

0.01

5.3% (1/19)

70% (7/10)

<0.001

13% ( 3/23)

81% (9/11)

<0.001

4.3% (1/23)

63% ( 7/11)

<0.001

a

b

Implantation rate (%,n/n) c
Clinical pregnancy rate per ET (%,n/n)

b

Live birth rate per ET (%,n/n) b
Clinical pregnancy rate per cycle (%,n/n)

b

Live birth rate per cycle (%,n/n) b

Data are presented as median (range) or percentages.
AC-FET: artificial cycle-frozen thawed embryo transfer; L-FET: letrozole-frozen thawed embryo transfer; NS: not
statistically significant; AFC: antral follicle count; ET: embryo transfer.
a
Mann–Whitney U test, b Fisher’s exact test, c chi-squared test.

to AC [1]. It was suggested that mild OS with letrozole
may overcome subtle defects in folliculogenesis, naturally
support luteal phase via development of corpus luteum
in patients with ovulation disorders [6,31], normalize
the increased aromatase P450 mRNA expression that is
related to poor IVF outcome, and improve endometrial
receptivity [46,47].

Hu et al. reported that letrozole-stimulated cycles
had significantly higher IR, CPR, and ongoing pregnancy
rate per ET when compared with artificial and human
menopausal gonadotropin (hMG) stimulated FET cycles of
patients with PCOS. In this retrospective pilot study, peak
estradiol levels were significantly lower in the letrozole
group than those in hMG group [48]. In a prospective
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randomized study of 1230 cycles with ovulatory disorders
showed that IR, CPR, and LBR were significantly higher
in the L-FET group when compared to the AC-FET
but similar with those of the natural cycle (NC) group.
Moreover, significantly lower abortion rate and estradiol
level on human chorionic gonadotropin (hCG) day
were also observed in the L-FET group [6]. Zhang et al.
also demonstrated increased LBR in the L-FET group
when compared to the AC-FET group in women with
polycystic ovary syndrome in a retrospective study [29].
Lastly, CPR was significantly higher and E2 levels on ET
day were significantly lower in the L-FET group compared
the AC-FET group in a prospective randomized study in
patients with normal menses [49]. In accordance with
these studies, we demonstrated statistically significantly
improved IR, CPR, and LBR with a lower peak E2 levels
and cancellation rates in L-FET cycles. Differently, we
had a study population of patients with a history of UPrelated cycle cancellation. Promising results of letrozole
on pregnancy outcomes and E2 levels encourage us for the
usage of letrozole in patients with UP history.
Limitations of our study were its retrospective
nonrandomized design and small sample size. Since the
number of patients in the groups of our study is low, it
is a possibility that statistical outcomes are by chance.
However, it is difficult to get enough patients that have UP
in a single center. The evaluation method of UP might be

a limitation. The number of UP per minute was calculated
as the number of peristaltic waveforms seen directly
in the endometrium in sagittal plane on transvaginal
ultrasound examination for 1 min. Although the counting
of visible waves seems to be subjective, the number of
peristaltic waveforms could be clearly noticed throughout
the endometrial cavity and it could be clearly counted in
patients. Due to the absence of a computer-assisted image
analysis system in our clinic, we had to select this method.
Another limitation was the usage of atosiban only in the
AC-FET group due to UP and there was not any control
group for atosiban in the L-FET group. The fact that the
embryo transfer days are not similar is another limitation
for this study. It was the advantage that LBR was the end
point.
In conclusion, letrozole seems to be a promising
protocol for the patients with a history of UP. However,
large sample sized randomized studies are needed to reach
certain conclusions.
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